All News
Polygenic Risk Scores to Identfy Severe Knee and Hip Osteoarthritis
Prevention of knee and hip osteoarthritis would obviate considerable disability and future surgery. We may be one step closer according to a prospective European GWAS study showing polygenic risk scores (PRSs) significantly associated with higher risks for knee and hip OA joint replacement.
Read Article
Diagnostic Delays in Spondyloarthritis Still Prolonged
Previously quoted average delay in diagnosing axial spondyloarthritis (axSpA) may be improving as a recent UK study shows the mean average time to diagnosis in two different NHS trusts was between five and six years.
Read Article
Acne with JAK Inhibitors
JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.
https://t.co/b9pX9NgZAx https://t.co/RL9vi3Xbf6
Links:
Dr. John Cush RheumNow ( View Tweet)
Prospective randomized trial of ultrasound-guided genicular nerve block (GNB) vs physical therapy (PT) i102 pts chronic knee #OA - GNB was superior at walk distance, pain, functional and physical capacity, at 12 weeks https://t.co/MOJ16zAiqH https://t.co/JJJye2dobH
Links:
Dr. John Cush RheumNow ( View Tweet)
Expansive (full read) review of CBD - legal and regulatory overview, availability, physiologic and pharmacologic effects, safety, & risks, standards, use in specific rheumatic disorders. https://t.co/hefwKTmPLK https://t.co/IZKZMOZ5ij
Links:
Dr. John Cush RheumNow ( View Tweet)
TOMORROW! Register for our 5/10 Tuesday Night Rheumatology on PsA Advances.
This webinar will feature highlights from:
PsA Guidelines
Arthur Kavanaugh, MD
Drug Targeting in PsA
Bruce Kirkham, MD
PsA Registries and Real World Data
Alexis Ogdie, MD
https://t.co/0fNuHz6wVy https://t.co/KssNJ41Wqz
Links:
Dr. John Cush RheumNow ( View Tweet)
DOCTORS: are you ready to attend big medical meetings ? @LCalabreseDO
Dr. John Cush RheumNow ( View Tweet)
Allopurinol Use Does Not Increase Mortality in Gout w/ Chronic Kidney Disease
A trial has shown that allopurinol use dose escalation and achieving target uric acid levels, was not associated w/ increased mortality in patients with gout and concurrent CKD.
https://t.co/8LHlRyTgS0 https://t.co/4Hu9cTwptO
Links:
Dr. John Cush RheumNow ( View Tweet)
Hyperuricemia as a biomarker of severe #PsA? Study of 242 PsA pts 30% had hyperuricemia & 6% had gout. Hyperuricemia was significantly associated with age, comorbidity, perph polyarthritis, Jt destruction, less response to treatment. https://t.co/U5wAQdWLdC https://t.co/QfoaogDeun
Links:
Dr. John Cush RheumNow ( View Tweet)
TLR7 signaling impt to SLE as it drives type I IFN & activation of autoreactive B cells. Nature reports missense TLR7 (Y264H) variant from severe lupus induces guanosine & cGMP & causes murine lupus when introduced into mice. https://t.co/VZioZfcJQ6 https://t.co/AtxWD4XGBF
Dr. John Cush RheumNow ( View Tweet)
Good free patient info handout on LUMBAR SPINAL STENOSIS from JAMA https://t.co/aDPwLzFvfQ
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase 2b DBRPCT of Intranodular injections of adalimumab in 140 pts w/ Dupuytrens contracture showed signif reduction nodule size and hardness ((−4·6 vs −2·2; p=0·0002) at 12 months https://t.co/9wBOeQNUdL https://t.co/HOR8rzYuRa
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Judith James on environmental factors that contribute to lupus risk and expression. #UTSWSLE2022 https://t.co/MGE51vlDMY
Dr. John Cush RheumNow ( View Tweet)
GALAXI-1 Study - Guselkumab effective in Crohn's Disease. 309 CD pts (1/2 refractory dz) Rx w/ either PBO, or IV GUS 200 mg, 600 mg, or 1200 mg at weeks 0, 4, and 8; At week 12, all 3 doses had signif. clinical and endoscopic improvements vs PBO https://t.co/iGyAmCoO96
Links:
Dr. John Cush RheumNow ( View Tweet)
RBCs from SLE patients retain mitochondrial proteins that may either lead to type I IFN or be taken up by myeloid cells. (V. Pascual) #UTSWSLE2022 https://t.co/VdQGRDUMvX
Dr. John Cush RheumNow ( View Tweet)
Dr. Pascual shows that signatures show IFN or plasmablast or PMN/Myeloid signatures, thus identifying 7 subsets of lupus kids #UTSWSLE2022 https://t.co/3BAxPdAKw8
Dr. John Cush RheumNow ( View Tweet)
DOCTORS: are you ready to attend big medical meetings ? @LCalabreseDO
Dr. John Cush RheumNow ( View Tweet)
Clinical evidence of type I IFNa excess expressed in clinical SLE (Dr. Virginia Pascual) #UTSWSLE2022 https://t.co/To2U9ZtxU3
Dr. John Cush RheumNow ( View Tweet)
Professor Chandra Mohan on pathogenesis and immunogenetics of #SLE - over 180 genes linked to the pathogenesis, modified by infection (bigger role for EBV?) hormones, smoking, hormonal status. #UTSWSLE2022 https://t.co/aKNpxZfdc6
Dr. John Cush RheumNow ( View Tweet)
Efficacy of Subsequent b/tsDMARD Use in Rheumatoid Arthritis
https://t.co/5dXe0AdNzE https://t.co/eS4KdaKBmC
Links:
Dr. John Cush RheumNow ( View Tweet)